Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer-Reference-Cited by-同舟云学术

Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer

Published:2013-05 Issue:5 Volume:24 Page:1219-1225
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Fan Y.,Xu B.H.,Yuan P.,Ma F.,Wang J.Y.,Ding X.Y.,Zhang P.,Li Q.,Cai R.G.

Funder

AVON® China breast cancer research

the National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/5/1219/13788810/mds603.pdf

Reference32 articles.

1. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry;Bauer;Cancer,2007

2. Triple negative tumours: a critical review;Reis-Filho;Histopathology,2008

3. Pattern of metastatic spread in triple-negative breast cancer;Dent;Breast Cancer Res Treat,2009

4. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC);O'Shaughnessy;J Clin Oncol,2011

5. The role of BRCA1 in the cellular response to chemotherapy;Kennedy;J Natl Cancer Inst,2004

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combinatorial Delivery of Docetaxel- and Erlotinib-Loaded Functionalized Nanostructured Lipid Carriers for the Treatment of Triple-Negative Breast Cancer Using Quality-by-Design Approach;Pharmaceutics;2024-07-11

2. Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HELEN-001): results from a multicenter, randomized controlled, open-label phase II trial;2024-04-11

3. Amplifying cancer chemoimmunotherapy through F4/80+CD11c+ DC-like macrophages induced by micellar docetaxel together with a TLR7/8 nanoagonist;Nano Today;2024-02

4. Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)✰;Journal of the National Cancer Center;2023-12

5. Functional inhibition of the RNA‐binding protein HuR sensitizes triple‐negative breast cancer to chemotherapy;Molecular Oncology;2023-07-19